At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
Ravulizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria
In Brief
A Phase 2 clinical trial evaluating Ravulizumab for Paroxysmal Nocturnal Hemoglobinuria and PNH. Completed, enrolled 26 participants across 16 sites in 7 countries.
Detailed Summary
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of multiple intravenous (IV) doses of ravulizumab administered to complement inhibitor treatment-naïve participants with PNH.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParoxysmal Nocturnal Hemoglobinuria, PNH
CountriesCanada, France, Germany, South Korea, Spain, Taiwan, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartJan 2016
Primary CompletionFeb 2017
Study CompletionJan 2022
TodayJul 2026
First PostedNov 17, 2015
Enrollment StartJan 4, 2016
Primary CompletionFeb 23, 2017
Study CompletionJan 12, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.6 years ago
Interventions
Ravulizumabbiological
All treatments were given as IV infusions.